The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery

NHS Trust

Status and phase: Completed; Phase 2; Phase 1

Conditions: Myocardial Reperfusion Injury; Cytoprotection

Treatments: Drug: Hyperbaric Oxygen

Study type: Interventional

Funder types: Other

Identifiers

NCT00623142

04/Q1104/26

R0047

Details and patient eligibility

About

The purpose of this study was to determine if treating patients who have coronary heart disease with hyperbaric oxygen (HBO) prior to coronary artery bypass graft (CABG) surgery reduces injury to the heart and vascular system during and after surgery. Furthermore, this study also aims to identify some of the post CABG clinical effects of HBO treatment prior to CABG.

Enrollment: 81 patients

Sex: All

Ages: 20 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing elective first time CABG
• Patients with at least 1 vessel coronary artery disease undergoing on- pump CABG

Exclusion criteria

• Age ≤ 20 years or ≥ 85 years
• Ejection fraction < 30%
• Unstable angina
• Recent myocardial infarction (< 1 month)
• Any additional cardiac disease (e.g. arrythmia, aneurysm, valvular/septal disease, dissection or elevated pulmonary artery pressure)
• Any end stage organ failure (e.g. renal and respiratory failure)
• History of chronic obstructive pulmonary disease (COPD)
• Pneumothorax
• Pulmonary bullae
• Convulsions
• Current history of malignancy
• Severe myopia or intraocular lens
• Patients on K+(ATP) Channel Openers e.g. Nicorandil, Oral Hypoglycemics, Opioid Analgesics, Catecholamines.

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

81 participants in 2 patient groups

A

No Intervention group

Description:

Patients in this arm were not treated with HBO prior to CABG

B

Experimental group

Description:

Patients in this arm were treated with HBO prior to CABG

Treatment:

Drug: Hyperbaric Oxygen